Co-Diagnostics (CODX) has a profit margin of -5527.61%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
Co-Diagnostics's profit margin stands at -5527.61% as of September 2026. That compares with -6336.27% in the prior-year period — up 12.8% year over year. That is below the Healthcare sector average of 17.63%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Co-Diagnostics reported -5527.61% in profit margin versus -6336.27% a year earlier — a 12.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
Co-Diagnostics sits lower the Healthcare benchmark (17.63%) with a profit margin of -5527.61%. That is roughly 31456.1% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A profit margin of -5527.61% for Co-Diagnostics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Co-Diagnostics's profit margin evolved across reporting periods, while the comparison chart places CODX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.